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Assessment of the quality and quantity 
of naturally induced antibody responses 
to EBA175RIII–V in Ghanaian children living 
in two communities with varying malaria 
transmission patterns
Hamza B. Abagna1,2, Festus K. Acquah1, Ruth Okonu1, Nii A. Aryee2, Michael Theisen3,4 and Linda E. Amoah1* 
Abstract 
Background: Recent global reports on malaria suggest significant decrease in disease severity and an increase in 
control interventions in many malaria endemic countries, including Ghana. However, a major driving force sustaining 
malaria transmission in recent times is the asymptomatic carriage of malaria parasites, which can enhance immune 
responses against parasite antigens. This study determined the prevalence and relative avidities of naturally induced 
antibodies to EBA175RIII–VLl in asymptomatic children living in two communities with varying malaria transmission 
patterns.
Methods: An asexual stage Plasmodium falciparum antigen, EBA175RIII–VLl was expressed in Lactococcus lactis, 
purified and used in indirect ELISA to measure total and cytophilic IgG concentrations and avidities in children aged 
between 6 and 12 years. The children were selected from Obom and Abura, communities with perennial and sea-
sonal malaria transmission, respectively. Venous blood samples were collected in July and October 2015 and again in 
January 2016. The multiplicity of infection and the genetic diversity of EBA175RIII circulating in both sites were also 
assessed using polymerase chain reaction.
Results: Asymptomatic parasite carriage in the children from Obom decreased from July (peak season), through 
October and January, however parasite carriage in children from Abura was bimodal, with the lowest prevalence 
estimated in October. Antibody concentrations over the course of the study remained stable within each study site 
however, children living in Obom had significantly higher EBA175RIII–VLl antibody concentrations than children living 
in Abura (P < 0.05, Mann–Whitney test). Over the course of the study, the relative antibody avidities of EBA175RIII–VLl 
IgG antibodies were similar within and between the sites.
Conclusion: Naturally acquired IgG concentrations but not relative antibody avidities to EBA175RIII–V were signifi-
cantly higher in Obom where malaria transmission is perennial than in Abura, where malaria transmission is seasonal.
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Background
Morbidity and mortality rates associated with malaria in 
sub-Saharan Africa although on the decline over the past 
few years, are still very high and a major public health 
concern [1]. Exposure to infection by Plasmodium fal-
ciparum, the major causative parasite for malaria in 
sub-Saharan Africa, results in the development of anti-
disease immunity [1] as well as non-sterile anti-parasite 
immunity, which can protect against high parasitaemia 
[2]. Maturity of immunity to malaria enables the host to 
harbour previously encountered P. falciparum parasite 
clones without showing signs of malaria [3–5]. Asymp-
tomatic parasite carriage can be either microscopic or 
submicroscopic and may persist for extended periods [6, 
7] and serve as reservoirs for malaria transmission as no 
treatment is sought [8].
Antibodies developed against a number of asexual P. 
falciparum sporozoite and merozoite antigens have been 
determined to be protective in humans [9, 10]. The eryth-
rocyte binding antigen 175 (EBA 175, Pf3D7_0731500) 
is a P. falciparum merozoite ligand that is implicated in 
erythrocyte invasion, as it is used by the parasite to bind 
to erythrocytes through interactions with the sialic acid 
residues of glycophorin A on the erythrocyte during 
merozoite invasion [11, 12]. EBA175 consists of 6 extra-
cellular regions, R1 through RVI [13]. RII, which consists 
of two cysteine rich Duffy binding domains, F1 and F2 
which have been identified as essential for receptor bind-
ing [12] has been produced as a recombinant antigen in 
Escherichia coli [14], Baculovirus [15] and Pichia pasto-
ris [16]. Naturally acquired antibody responses against 
recombinant RII have been suggested to inhibit the mer-
ozoite binding to glycophorin A, inhibit invasion in vitro 
and provide protection against clinical malaria [11, 12, 
16–20]. RIII–IV comprises of a dimorphic region, RIII, 
which is used to distinguish between the FCR3 ‘F’ and 
CAMP ‘C’ parasite variants [13] as well as the highly con-
served RIV and RV regions [7]. EBA175RIII–V has been 
expressed in E. coli [11, 17, 21] and naturally-induced 
antibodies against the RIII–V region [20, 21] have been 
suggested to offer protection against disease in some 
studies [17, 22]. Antibodies against region IV–V of EBA 
175 have been shown to have strain transcending growth 
inhibitory properties, which are more potent than anti-
bodies against the RII region [23] and more significantly 
correlated with protection against clinical malaria in 
children [24]. A recent report suggests that antibodies 
against RIII–V offer similar levels of protection as a 200-
fold excess of antibodies against RII [25], suggesting anti-
bodies against RIII–V are more potent than antibodies 
against RII.
Exposure to malaria parasites in perennial transmis-
sion settings is expected to be higher than in seasonal 
transmission settings. Repeated exposure to malaria anti-
gens is expected to increase antibody affinity and result 
in an increase in antibody avidity [26], however, some 
reports on avidity of malaria antibodies have suggested 
otherwise. One report has suggested that increased 
exposure to P. falciparum parasites did not result in an 
increase in the relative antibody avidity to merozo-
ite antigens including MSP1 and MSP3 [26]. An earlier 
study on Gambian children also failed to find an asso-
ciation between asymptomatic P. falciparum carriage 
and antibody avidity [27] despite the fact that asympto-
matic infections repeatedly expose the host to the para-
site, which should boost immune responses and enhance 
affinity maturation. These studies put together suggest 
that more studies are needed to understand the func-
tions of anti-EBA175RIII–V antibodies as well as under-
stand how antibody concentrations and avidity influence 
asymptomatic P. falciparum carriage.
In this study, a new recombinant linear fragment of 
EBA175RIII–V, EBA175RIII–VLl was produced in Lacto-
coccus lactis and used to monitor changes in the quality 
and quantity of naturally acquired anti-EBA175 antibod-
ies in school children aged between 6 and 12 years, living 
in two communities of varying malaria parasite preva-
lence in southern Ghana.
Methods
Study site and population
A multiple cross-sectional study was conducted on a 
cohort of 137 children aged between 6 and 12 years. The 
children were recruited from two public primary schools, 
one in Obom, in the Obom Domeabra constituency of 
the Greater Accra Region, and the other in Abura in the 
Cape Coast metropolis of the Central Region (Fig.  1), 
both within the coastal savanna zone of Ghana. The peak 
malaria season in both sites is between July and August 
but malaria transmission in Obom is perennial and sea-
sonal in Abura [28]. None of the children who were sam-
pled exhibited any signs of clinical malaria.
Sample collection and processing
The children recruited in this study were part of a larger 
study where children were recruited into a multiple 
cross-sectional study that began in February 2015 and 
ended in January 2016. A total of 64 children from Obom 
and 73 children from Abura who were present dur-
ing the July 2015 (peak malaria season), October 2015 
(end of peak season) and January 2016 (off peak season) 
sampling visits were selected for this study. During each 
collection, 5 ml of venous blood was collected into acid 
citrate dextrose (ACD) vacutainer tubes and used to 
prepare thin and thick blood smears (for species identi-
fication and parasite density estimation, respectively) as 
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well as to spot filter paper. The filter paper samples were 
air-dried and stored desiccated at room temperature for 
DNA extraction within a week of the collection. Plasma 
was separated by centrifugation from the whole blood 
and stored frozen at − 20 °C until required.
Estimation of parasite density
Thick and thin blood smears were processed and 
observed under ×100 oil immersion using a light micro-
scope [29]. The blood smears were subsequently read by 
two independent microscopists. The number of infected 
erythrocytes was counted against 200 white blood cells 
(WBCs) and then multiplied by 40, based on the assump-
tion that 1 μl of blood contains 8000 WBCs to yield the 
parasite density [30]. Plasmodium species identification 
was based on morphological differences between species.
Parasite genotyping
Extraction of genomic DNA
DNA extraction was carried out using the Chelex extrac-
tion method as previously described [31] with minor 
modifications. Briefly, two discs of the dried filter paper 
blood-spots (DBS) were punched using a 3  mm paper 
punch into a 1.5  ml microcentrifuge tube containing 
1120  μl of 0.5% saponin (0.5  g saponin (Sigma-Aldrich, 
USA) in 100  ml phosphate buffered saline (Sigma-
Aldrich, USA), pH 7.4 (PBS) solution. The tubes were 
vortexed and then left shaking on a shaking incubator 
overnight at room temperature. The saponin solution was 
subsequently decanted, the discs washed twice with 1 ml 
of ice-cold PBS and centrifuged for 10 min at 10,000×g. 
A 150 μl aliquot of 6% Chelex-100 (Sigma-Aldrich, USA) 
in DNase/RNase-free water was added to each disc. After 
a 5-min incubation at 95  °C the tubes were centrifuged 
at 14,000×g and the DNase/RNase-free water contain-
ing the extracted genomic DNA carefully pipetted into a 
labelled tube and stored at − 20 °C until further use.
Molecular characterization of P. falciparum parasites
Amplification of the 18sRNA from P. falciparum [32] was 
used to determine the prevalence of asymptomatic infec-
tion in children in each site during all the three sample 
collection time points. Briefly, the primary PCR reac-
tion consisted of 5 μl of genomic DNA (gDNA), 200 nM 
Fig. 1 Map of Ghana projecting the location of the study sites Obom and Abura in southern Ghana
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dNTPs, 2 mM  MgCl2, 133 nM each of forward (rPLU6) 
and reverse (rPLU5) primers (Additional file 1) and 1 U 
OneTaq DNA polymerase (New England Biolabs, UK). 
The nested PCR consisted of a similar reaction mix as the 
primary reaction, except that the primers were replaced 
with rFal1 (forward) and rFal2 (reverse) and 2  μl of the 
primary product was used as the template. The positive 
control used for the speciation reaction was gDNA from 
the 3D7 strain of P. falciparum (MRA 102G).
The RIII domain of EBA175 (EBA175RIII) was ampli-
fied from DNA extracted from samples collected in July 
and October using semi nested PCR with primers listed 
in Additional file 1. Briefly, 4 μl of genomic DNA (gDNA) 
was amplified using a PCR reaction mixture that consisted 
of 200 nM dNTPs, 2 mM  MgCl2, 133 nM each of forward 
and reverse primers (R3F and R5R for the primary reac-
tion and R3F and R3R for the secondary reaction), and 0.5 
units of One Taq DNA polymerase. PCR products were 
separated on 2% ethidium bromide-stained agarose gels 
and visualized under UV illumination. Genomic DNA 
for P. falciparum strains K1 (MRA 159G) and 3D7 (MRA 
102G), obtained from MR4, were used as positive controls 
for the PCR genotyping reactions.
Multiplicity of Plasmodium falciparum parasite infection
The merozoite surface protein 1 (msp1) and merozoite 
surface protein 2 (msp2) genes were amplified from the 
extracted DNA from samples collected in July using a 
similar process to that described in an earlier study [33]. 
Briefly, the highly polymorphic block 2 region of msp1 
and block 3 of msp2 were amplified using family specific 
nested polymerase chain reaction (PCR). The primary 
15 μl reaction contained ~ 10–50 ng of extracted DNA, 
0.2 mM dNTP mix, 2 mM  MgCl2, 0.2 mM each of a com-
bination of forward and reverse primers for both msp1 
and msp2 and 0.5 units of OneTaq Polymerase. The fam-
ily specific msp1 and msp2 secondary reactions mixture 
were similar to the primary, however, 1 μl of the primary 
PCR product was used as template and family specific 
primers (Additional file 1) were used. A negative control 
(no template) and positive controls for each allelic fam-
ily (msp1: MRA-159G for KI, MRA-155G for MAD20 
and MRA-200G for the RO33, msp2: MRA-102G for 
3D7 and MRA-155G for FC27) were included in the PCR 
reactions.
Production of EBA175RIII–VLl
The EBA175RIII–V fragment (2280–3900 bp) was ampli-
fied from gDNA extracted from the 3D7 P. falcipa-
rum parasite strain (‘F’ allele) and produced in L. lactis 
using the same expression vector and host as previously 
described for the production of  Pfs230LlC0 [34] and prim-
ers listed in Additional file 1. Briefly, the EBA 175 RIII–V 
gene was amplified from gDNA extracted from the 3D7 
strain of P. falciparum using the 3RF and the R5R prim-
ers listed in Additional file  1. The PCR amplicon was 
subsequently treated with BglII and BamHI and purified 
using the DNA Clean & Concentrator™-25 kit (Zymo). 
The vector, pLEA2 [35] was digested with BglII, dephos-
phorylated using alkaline phosphatase and purified from 
a 1% agarose gel. The vector and fragment were ligated 
using T4 DNA ligase, transformed into max efficiency 
DH5α competent cells according to manufacturer’s 
instructions and plated on LB plates containing 250 μg/
ml erythromycin. Colonies containing the EBA175RIII–
V plasmid were grown in selective media and plasmids 
isolated using the EZNA plasmid purification kit (Omega 
Biotek, USA) according to manufacturer’s protocol. The 
plasmids were sent for commercial sequencing (Inte-
grated DNA Technology, GE).
Expression of EBA175‑RIII–VLl
A procedure similar to that previously described for 
the production of  Pfs230LlC0 [34] was used. Briefly, the 
pLEA2.EBA175RIII–V plasmid was transformed into 
competent L. lactis strain MG1363 using the Gene Pul-
ser (BIORAD, USA). Transformed cells were then plated 
on Yeast Peptone Dextrose media (YPD) plates contain-
ing 5  µg/ml erythromycin and then incubated at 30  °C. 
Transformed L. lactis colonies were screened for pro-
tein expression by inoculating a colony into 5 ml of YPD 
media supplemented with 10  µg/µl erythromycin over-
night. The culture was subsequently harvested via cen-
trifugation at 4500×g for 10  min and the supernatant 
subjected to SDS-PAGE analysis.
Large scale production of EBA175RIII–VLl was  pre-
pared by inoculating a biofermentor [35, 36] containing 
1  L of YPD supplemented with 10  µg/µl erythromycin 
and set at 30 °C and pH 6.5 with a clone of EBA175RIII-
V. After 4–5 h of stationary phase growth (~ 14 h of total 
growth), the culture was harvested by centrifugation at 
10,000×g for 20 min.
Protein purification and characterization
The culture supernatant was clarified by filtration 
through a 20 µm filter and then purified by affinity chro-
matography (AC) over a 5 ml HisTrap Ni–NTA column 
(GE healthcare, USA) using an AKTAxpress purifica-
tion system (GE healthcare, USA) with wash/equilibra-
tion buffer (50  mM sodium phosphate pH 7.0/250  mM 
sodium chloride/20  mM imidazole) and elution buffer 
(wash buffer supplemented with 200 mM imidazole).
A 15  µl aliquot of the clarified culture supernatant as 
well as 15  µl of a tenfold diluted affinity purified pro-
tein were subjected to SDS-PAGE analysis as previ-
ously described [34]. The gels were either stained with 
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Coomassie blue or subjected to western blot analysis. 
The western blot was probed with penta-His mouse 
IgG1 monoclonal  antibodies (Thermo Scientific, USA) 
followed by alkaline phosphatase conjugated goat anti 
mouse IgG (H +  L) secondary antibodies (Thermo Sci-
entific, USA). The blot was finally developed using 
1-step nitro-blue tetrazolium and 5-bromo-4-chloro-
3′-indolyphosphate (NBT/BCIP) substrate solution 
(Thermo Scientific, USA).
Enzyme‑linked immunosorbent assay (ELISA)
Enzyme linked immunosorbent assays were performed 
using a protocol similar to that previously reported 
by Acquah et  al. [34]. Briefly, 100  µl of purified protein 
EBA175-RIII–VLl diluted to 1  µg/ml in PBS was coated 
onto NUNC maxisorp™ ELISA plates overnight at 4  °C. 
Plates were washed four times using PBS supplemented 
with 0.05% Tween 20 (PBS/T) and blocked with 3% (w/v) 
skimmed milk powder (Marvel, UK) in PBS/T. Recombi-
nant polyclonal human IgG (PB055) was used as a stand-
ard, at a starting concentration of 1000 ng/ml (100 µl) and 
serially diluted threefold for 7 additional concentrations. 
The plates were then incubated for an hour with 100 µl/
well of test plasma or a negative control (malaria naïve) 
sample consisting of a pool of malaria naïve plasma all 
diluted 200-fold at room temperature, and then washed 
four times with PBS/T. The plates were subsequently 
incubated with goat anti-human IgG-HRP secondary 
antibodies (Invitrogen, USA). All plates were developed 
by adding 50 µl of 3,3′,5,5′-tetramethylbenzidine (TMB) 
solution for 15 min and then stopped with 50 µl of 2 M 
 H2SO4. Absorbance of coloured products of the reaction 
was measured immediately after stopping the reactions 
at a wavelength of 450 nm.
IgG1 and IgG3 ELISA
A procedure similar to that described above for IgG was 
used with some minor modifications. Basically, the test 
samples were diluted 1:50 and the standard used was a 
pool of plasma previously identified as having high IgG1 
and IgG3 concentrations at a starting concentration of 
1:50 and diluted twofold for 6 extra dilutions. The plates 
were processed as above. The temperature setting for the 
1  h sample incubation was increased to 37  °C and the 
secondary antibodies used were goat anti-human IgG1 
and IgG3, respectively.
Relative avidity ELISA
A procedure similar to the total IgG ELISA described 
above was used, however the plasma samples after the 1 h 
incubation were washed three times and then incubated 
with 2.4 M sodium thiocyanate (NaSCN) for 10 min and 
then subsequently washed off thrice with PBS/T prior to 
the addition of the secondary antibody [26, 37]. Avidity 
for the subclass proceeded similar to the subclass ELISA 
with the added NaSCN step.
Data analysis
The physical and chemical properties of the antigen were 
obtained using ProtParam [38]. ELISA data was entered 
into Excel, converted to antibody concentrations using 
ADAMSEL (Ed Remarque) and analysed using Graph-
Pad Prism v5 and the R statistical software (Version 
3.4.0). The frequency and other column statistics includ-
ing T-tests and One way ANOVA (Kruskal–Wallis) tests 
were determined using GraphPad Prism v5. A non-par-
ametric correlation (Spearman, GraphPad Prism) was 
used to assess correlation between age and antibody con-
centration and antibody avidity.
The R statistical software (Version 3.4.0) was used for 
the assessment of antibodies against EBA175. To project 
asymptomatic parasite carriage during the subsequent 
sampling time point in the school children, a mixed 
effects regression model for repeated measurements 
was fitted to antigen-specific antibody data using the R 
package lme4 [39]. Initially, antigen-specific antibody 
data and relative avidity data were log2 transformed and 
entered into the model as fixed effects with age as an 
interaction term, whilst visit time point and town were 
entered as random effects. This model was compared to 
other models that dropped the age interaction term or 
one of the random effects, and the best model, based on 
the lowest AIC values was selected for further analysis. 
The best model had log2 transformed antibody level and 
log2 relative avidity index (RAI) transformed as the fixed 
effect and study town as a random effect since the inter-
action term (age) and visit time point did not significantly 
contribute to the models. P-values for the intercept and 
fixed effect were obtained by likelihood ratio tests (with 
Laplace Approximation) (Table 3).
The relative avidity index (RAI) for an antibody was 
calculated as the ratio of the mean IgG concentration of 
the sodium thiocyanate-treated sample to the mean IgG 
concentration of the untreated sample multiplied by 100 
(Avidity index  =  [antibodies following Sodium thiocy-
anate (NaSCN) treatment/antibodies without NaSCN 
treatment] × 100). Statistical significance was defined as 
P ≤ 0.05 unless otherwise stated.
Data from healthy (non parasitaemic) children were 
excluded from all analysis that compared antibody 
responses (concentration and avidity) between the three-
time points.
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Results
The study used samples from 137 school children 
between 6 and 12 years of age. The number of asympto-
matic children detected by the microscopic evaluation 
of thick blood smears ranged between 10.9 and 71.9% in 
Obom and 17.8–58.9% in Abura (Table 1) and identified 
the presence of Plasmodium malariae mono infections in 
four children from Obom in July. Asymptomatic parasite 
carriage determined by PCR ranged between 59.4 and 
68.8% in Obom and 18.9–75.3% in Abura (Table 1). The 
mean age (standard error of mean, SEM) of the school 
children was 9.09 (0.215) years in Obom and 8.79 (0.178) 
years in Abura was not significantly different between the 
two sites (P  >  0.05, Mann–Whitney test). The geomet-
ric mean P. falciparum parasite density (PD) reduced in 
moving from July (the peak) through October (the end of 
the peak) to January (the off peak) season in both sites, 
with PD in July being significantly different from PD 
in both October and January in both Obom (P  <  0.05, 
Dunn’s Multiple Comparison Test) and Abura (P < 0.001, 
Dunn’s Multiple Comparison Test).
Parasite genotyping
The geometric mean multiplicity of infection (95% confi-
dence interval) determined by genotyping the msp1 gene 
for asymptomatic parasite infection in Obom in July was 
2.094 (1.873–2.341), which was significantly (P < 0.0001, 
Mann–Whitney two-tailed test) higher than 1.397 
(1.238–1.577) determined in the asymptomatic children 
living in Abura in the same month.
Agarose gel electrophoresis of the EBA175RIII PCR 
amplicons yielded fragments that were either  ~  740  bp 
(‘C’ allele) or ~ 820 bp (‘F’ alleles). The band sizes are dif-
ferent from the 715 and the 795  bp fragments that are 
characterized by amplification of RIII using the primers 
EBA1, 2, 3 and 4 [22] due to the use of the antigen clon-
ing primers for the reactions (Additional file 1: Table S1). 
Parasites identified in almost all of the samples genotyped 
predominantly belong to a single allelic family, with only 
one sample from Obom containing parasites belong-
ing to both allelic families. The ‘F’/’C’ allelic ratio ranged 
from 1.1 in Obom to 1.2 in Abura (Table 2).
Production of recombinant EBA175RIII–VLl
The 1620 bp region of EBA175 (bp 2280–3900) (Fig. 2a), 
representing RIII–V was successfully expressed as a 
secreted protein in L. lactis MG1363. Recombinant 
EBA175RIII–VLl (amino acid 760–1300 of EBA175) 
was purified from culture supernatants on a HisTrap FF 
Crude column (GE Healthcare, DK) yielding a ~ 125 kDa 
product (Fig.  2b). Purified antigen was used to assess 
naturally acquired immune responses to EBA 175 and the 
relative avidity of these antibodies.
Table 1 Characterization of study participants
Data presented from samples collected from 64 and 73 children living in Obom 
and Abura respectively
a Four children in Obom carried P. malariae mono infections
P. falciparum PCR (%) Microscopy (%)
Abura
 July 75.3 58.9
 Oct 18.9 17.8
 Jan 52.1 30.1
Obom
 July 68.8 71.9a
 Oct 67.2 26.6
 Jan 59.4 10.9
Table 2 Allelic distribution of EBA175
The percentages of the alleles with the exact count in brackets
Allele Abura (%, N) Obom (%, N)
F 54 (34) 51.6 (33)
C 46 (29) 46.9 (30)
F + C 0 1.6 (1)
a
b c
Fig. 2 Plasmodium falciparum EBA175RIII–V construct and expressed 
antigen. A schematic representation of the 1620 bp region of 
EBA175RIII–V cloned into the pLEA2 expression vector, which 
contains the nucleotide sequence of a hexahistidine tag inframe of 
the multiple cloning site (a). The culture supernatant (1) containing 
the secreted protein as well as the purified protein (2) was analysed 
by SDS-PAGE followed by coomassie staining (b) and a western blot 
probed with penta-His mouse monoclonal antibody (IgG1) (c)
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Characterization of naturally acquired antibody responses 
against EBA175RIII–VLl
There was no significant change (P  >  0.05, Dunn’s mul-
tiple comparative test) in the median concentrations of 
antibodies against EBA175RIII–VLl over the course of 
the changing malaria seasons in asymptomatic children 
from both Obom and Abura (Fig. 3a). However, antibody 
responses measured at each time point in Obom were 
significantly higher [P  <  0.0001 (July), 0.0005 (October) 
and 0.0001 (January), Mann–Whitney test] than those 
measured in Abura. The general decrease in antibody 
concentrations observed in moving from July (the peak) 
to October (off-peak season) in Obom was not appar-
ent in Abura (Fig.  3a). The trends in IgG responses to 
EBA175RIII–VLl in the children were similar to those 
against the non-repetitive domain of P. falciparum Glu-
tamate Rich Protein (GLURP.RO) (Additional file 2). The 
relative avidity indices of antibodies measured in Obom 
were generally lower than in Abura (Fig. 3b), however, no 
significant difference was identified in the median RAI 
of IgG in July, October and January in either Abura or 
Obom (P > 0.05, Dunn’s multiple comparative test).
The levels of IgG1 and IgG3 antibodies were signifi-
cantly higher in asymptomatic children from Obom 
compared to the asymptomatic children from Abura 
(Mann–Whitney test, P  =  0.0002 and 0.0410, respec-
tively) (Fig. 4a, b).
The concentration of IgG antibodies to EBA175RIII–
VLl in asymptomatic children from both Obom and 
Abura did not correlate significantly with age at any time 
point (P > 0.05, Spearman r = 0.3032, 0.2171 and 0.1597 
in Obom and −  0.04814, 0.3033 and 0.04804 in Abura 
for July, October and January, respectively). Fewer chil-
dren with high antibody avidities in July and October 
harboured parasites in the subsequent visit, October and 
January, respectively (Table 3).
Discussion
The early identification of the function RII and protec-
tive properties of antibodies against EBA175RII led to 
it gaining vaccine candidate status several years ago 
[18, 40]. The function of RIII–V has still not been con-
firmed [25] and the functions of antibodies against 
RIII–V of EBA175 have not been as extensively charac-
terized as RII most likely due to the dimorphic nature 
of RIII. EBA175 RII was earlier classified as highly con-
served [41], although some studies have identified RII 
to be highly polymorphic [42, 43] and anti-EBA175R2 
antibodies not to be associated with protection [44, 45]. 
Naturally induced antibodies against E. coli produced 
EBA175RIII–V has been found to be protective [25, 
46] and mice anti-EBA175RIII–V suggested to exhibit 
strain-transcending activity [23]. However, more studies 
are needed to characterize the functions of antibodies 
against EBA175RIII–V.
In this study, a new recombinant EBA175RIII–VLl was 
produced and used to evaluate changes in the quan-
tity and quality of naturally induced antibody responses 
developed against EBA175RIII–V in asymptomatic chil-
dren living in communities with varying malaria trans-
mission intensity across changing malaria seasons.
The recombinant antigen was produced in high yields, 
similar to that of  Pfs230C0Ll [34] and purified using a 
similar one-step purification process as  Pfs230C0Ll [34]. 
The antigen migrated as a ~ 125 kDa protein on a poly-
acrylamide (PAGE) gel (Fig. 2b, c), although the theoreti-
cally calculated size of the protein is ~ 60 kDa. A similarly 
large size antigen was produced when EBA175RIII–V 
was expressed in E. coli [23]. This migratory pattern could 
be a result of the antigen having a high negative charge 
and a grand average of hydropathicity (GRAVY) score of 
−  1.384. Proteins with low GRAVY scores are noted to 
Fig. 3 Characterization of IgG responses against EBA175RIII–VLl. Anti-
body concentrations (ng/ml) of plasma obtained from the enrolled 
children from Obom and Abura (a) diluted 1:200 was determined 
using indirect ELISA and a EBA175RIII–VLl as the antigen coated onto 
the ELISA plate and goat anti-human IgG used as the secondary 
antibody. The relative avidities of these same plasma samples were 
determined using a modified indirect ELISA assay where an incuba-
tion of the bound plasma samples obtained from children Obom 
and Abura (b) were treated with sodium thiocyanide is incorporated 
into the protocol. Plasma samples were obtained from whole blood 
collected from the children during the months of July 2015, October 
2015 and February 2016. Data in the graphs are represented as the 
median with the interquartile range
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migrate slower than expected on SDS-PAGE gels [47]. A 
similar phenomenon was observed after the production 
and purification of PfGLURP in L. lactis. PfGLURP is a 
negatively charged protein, which lacks tryptophan resi-
dues and migrated at ~ 92 kDa although the theoretical 
size is ~ 55 kDa [48]. EBA175RIII–VLl was produced in 
L. lactis due to the similar codon usage between L. lactis 
and P. falciparum, and the fact that the fragment did not 
require disulfide bridge formation. Lactococcus lactis has 
also been used for the successful production of a number 
of malaria vaccine candidates including GMZ2 [49] and 
R0.6C [35] and antigens such as  Pfs230C0Ll [34].
The geometric mean parasite density determined in 
July was significantly higher than that recorded in Octo-
ber and January in both Obom and Abura although the 
prevalence of children harbouring asymptomatic P. fal-
ciparum parasites determined by PCR remained sta-
ble over the same period in Obom. The prevalence of 
P. malariae and possibly other Plasmodium species 
could have been higher if more sensitive molecular tools 
were employed. The prevalence of P. malariae, the sec-
ond most predominant Plasmodium species in Ghana 
has recently been reported to be as high as 12.7% in the 
tropical rainforest zone of Ghana [50]. The distribution 
of parasites with different eba175 alleles in the asympto-
matic children from both Obom and Abura were similar, 
with an F/C ratio ranging between 1.1 in Obom and 1.2 
in Abura (Table  2). Genetic diversity in EBA175RIII–
V has been suggested to be limited [23] and the allelic 
distribution patterns found to be relatively stable over 
extended periods of time [51, 52]. The genotyping data 
did not portray the usual high prevalence of ‘F’ allele 
compared to the ‘C’ as has been previously reported in a 
number of West African countries including Ghana [22, 
51, 53]. However, these previous studies were conducted 
on symptomatic samples. The geometric mean multiplic-
ity of infection in asymptomatic children in Obom was 
significantly higher than that estimated for the children 
living in Abura, most likely due to the higher levels of 
malaria transmission in Obom compared to Abura.
Naturally-induced antibody responses to EBA175RIII–
VLl, a ‘F’ type antigen was high in Obom and low in 
Abura. The even distribution of the dimorphic EBA175 
alleles in both sites likely did not preferentially influence 
the antibody responses in either site. Naturally induced 
IgG responses in Obom were significantly (P  <  0.001, 
Mann–Whitney test) higher in Obom than those meas-
ured in Abura (Fig.  3a, b) most likely due to increased 
exposure to parasites by children living in the perennial 
transmission setting, Obom compared to Abura, the 
seasonal transmission setting (Table  1a). The median 
IgG concentrations of EBA175RIII–VLl measured in 
children from Obom at all the time points were sig-
nificantly (P < 0.0001, Mann–Whitney test) higher than 
those measured in Abura, even in July when the preva-
lence of asymptomatic parasite carriage estimated by 
both microscopy and PCR was higher than in Obom. 
This finding supports earlier studies that used natu-
rally acquired antibody responses to merozoite antigens 
Fig. 4 Characterization of cytophilic antibody responses. IgG1 (a) and IgG3 (b) antibody concentrations to EBA175RIII–VLl in asymptomatic children 
from Obom and Abura measured in the peak malaria season (July). Processes similar to that described in Fig. 3 were used to determine the con-
centrations and avidity of IgG1 and IgG3, the only difference was that goat anti-human IgG1 and goat anti-human IgG3 secondary antibodies were 
used in place of the goat anti-human IgG. The graphs represent the median antibody concentrations with interquartile range as error bars
Table 3 Influence of antibody concentration and relative 
avidity index (RAI) on the future carriage of P. falciparum 
parasites in different malaria transmission settings
Conc. antibody concentrations in ng/ml, RAI relative avidity index
* P < 0.05
Fixed effects Estimate std Error z value Pr (> |z|)
(Intercept) 0.4623 3.9658 0.117 0.9072
log2(Conc) 0.1397 0.1345 1.038 0.299
log2(RAI) 0.5251 0.2379 2.207 0.0273*
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including the apical membrane protein 1 (AMA1) and 
the merozoite surface protein 1 (MSP1) to differentiate 
between communities with different malaria transmis-
sion intensities [54–57].
No significant differences were observed in the median 
IgG concentrations of anti-EBA175RIII–V antibod-
ies across the different malaria seasons in both Obom 
and Abura. This could be a result of boosting of anti-
body responses by the presence of infecting parasites in 
asymptomatic children, whose prevalence was main-
tained between October and January in both sites. This 
supports the suggestion that the presence of concur-
rent parasitaemia has been found to increase antibody 
responses to EBA175 antigens [24].
The IgG subclass responses against EBA175 have been 
suggested to be predominantly cytophilic (IgG1 and 
IgG3) [58, 59]. IgG1 and IgG3 responses to EBA175RIII–
V have also been associated with lower parasitaemia and 
protection from malaria [17, 59, 60]. In this study IgG1 
and IgG3 levels in children from Obom in July were 
higher than those from Abura (Fig. 4), which was not sur-
prising as total IgG levels were also significantly higher in 
Obom than in Abura.
The relative avidity index (RAI) of IgG antibod-
ies against EBA175RIII–VLl was significantly inversely 
associated with parasite carriage during the subsequent 
quarterly visit (Table  3). The relative avidity of antibod-
ies against EBA175RIII–VLl in Obom was generally lower, 
although not significantly different from those measured 
in Abura (P > 0.05, paired t test) (Fig. 3c, d). The low avid-
ity of antibodies in Obom support previous studies that 
have suggested impaired affinity maturation to malaria 
antigens in settings with high perennial exposure to 
malaria parasites [61]. Maturation of humoral immune 
responses is expected to result in the production of anti-
bodies with increased avidity [62, 63], however, constant 
parasite carriage in areas with high perennial malaria 
transmission, such as Obom can result in reduced anti-
body affinities as has been previously reported [64].
Limitations
Plasmodium falciparum parasites were the only species 
of malaria parasites characterized by PCR in the study. 
The children were also not followed actively or passively 
so could have had additional exposure to P. falciparum 
parasites that were not captured at the sampling time 
points.
Conclusion
Naturally acquired IgG concentrations but not relative 
antibody avidities to EBA175RIII–V were significantly 
higher in Obom where malaria transmission is perennial 
than in Abura, where malaria transmission is seasonal.
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